Supported by CAMS Innovation Fund for Medical Sciences,No.2023-I2M-C&T-B-043;National High Level Hospital Clinical Research Funding,No.2022-PUMCH-B-015;CAMS Innovation Fund for Medical Sciences,No.2021-1-12M-002;Beijing Municipal Natural Science Foundation,No.M22014.
BACKGROUND There is a lack of clinical evidence on the efficacy and safety of transitioning from a thrice-daily pre-mixed insulin or basal-prandial regimen to insulin degludec/aspart(IDegAsp)therapy,with insufficient ...
Dear Dr. Martin Hovland, We learned from the literature that premixed insulins are short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting insulin in a fixed ratio, addressing FBG and PPBG...
Objective: To analyse the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in a Jordanian subgroup of the 24-week, non-interventional A1chieve study. Methods: A total of 509 Jordanian patients with ty...